Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | PNP | P00491 | 4/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HBB | P68871 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanine SCHEMBL2138874 | 0.88 | ALDH1A1 (0.49) | KDM4EALDH1A1LMNAGLAPMP22 | |
| Guanine SCHEMBL9900660 | 0.88 | ALDH1A1 (0.49) | KDM4EALDH1A1LMNAGLAPMP22 | |
| Guanine SCHEMBL5259 | 0.87 | ALDH1A1 (0.61) | KDM4EALDH1A1LMNAGLAPMP22 | |
| Guanine SCHEMBL4658042 | 0.87 | ALDH1A1 (0.61) | KDM4EALDH1A1LMNAGLAPMP22 | |
| Guanine SCHEMBL28373862 | 0.86 | ALDH1A1 (0.59) | KDM4EALDH1A1LMNAGLAPMP22 | |
| Guanine SCHEMBL865492 | 0.86 | ALDH1A1 (0.59) | KDM4EALDH1A1LMNAGLAPMP22 | |
| Guanine SCHEMBL4063556 | 0.86 | ALDH1A1 (0.59) | KDM4EALDH1A1LMNAGLAPMP22 | |
| Guanine SCHEMBL21611717 | 0.86 | ALDH1A1 (0.59) | KDM4EALDH1A1LMNAGLAPMP22 | |
| Guanine SCHEMBL2895087 | 0.86 | ALDH1A1 (0.59) | KDM4EALDH1A1LMNAGLAPMP22 | |
| Guanine SCHEMBL9512016 | 0.86 | ALDH1A1 (0.59) | KDM4EALDH1A1LMNAGLAPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9932646-B2 | Detection and use of antiviral resistance mutations | ABL SA (LU) | 2018-04-03 | — | — | US | disclosed |
| US-9702005-B2 | Hepatitis B viral variants with reduced susceptibility to nucleoside analogs and uses thereof | ABL SA (LU) | 2017-07-11 | — | — | US | disclosed |
| US-9701982-B2 | Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof | ABL SA (LU) | 2017-07-11 | — | — | US | disclosed |
| US-9682109-B2 | Antiviral resistance mutants and applications thereof | ABL SA (LU) | 2017-06-20 | — | — | US | disclosed |
| US-20160032410-A1 | DETECTION AND USE OF ANTIVIRAL RESISTANCE MUTATIONS | BARTHOLOMEUSZ ANGELINE INGRID (AU) | 2016-02-04 | — | — | US | disclosed |
| EP-1948800-B1 | ANTIVIRAL RESISTANCE MUTANTS AND APPLICATIONS THEREOF | MELBOURNE HEALTH (AU) | 2015-12-23 | — | — | EP | disclosed |
| US-8859198-B2 | Detection and use of antiviral resistance mutations | ABL SA (LU) | 2014-10-14 | — | — | US | disclosed |
| US-20140296504-A1 | HEPATITIS B VIRAL VARIANTS WITH REDUCED SUSCEPTIBILITY TO NUCLEOSIDE ANALOGS AND USES THEREOF | ABL SA (LU) | 2014-10-02 | — | — | US | disclosed |
| EP-1476543-B1 | VIRAL VARIANTS WITH ALTERED SUSCEPTIBILITY TO NUCLEOSIDE ANALOGS AND USES THEREOF | MELBOURNE HEALTH (AU) | 2014-05-14 | — | — | EP | disclosed |
| US-8592143-B2 | Hepatitis B viral variants with reduced susceptibility to nucleoside analogs and uses thereof | ABL SA (LU) | 2013-11-26 | — | — | US | disclosed |
| US-20060051743-A1 | Screening nucleic acid comprising sequence that encodes reverse transciptase domain of DNA polymerase for adefovir-resistant mutations; use in vaccine development | EVIVAR MEDICAL PTY LTD. (AU) | 2006-03-09 | — | — | US | disclosed |
| CN-1656109-A | Non-nucleoside reverse transcriptase inhibitors | GILEAD SCIENCES INC (US) | 2005-08-17 | — | — | CN | disclosed |
| US-20050153279-A1 | Viral variants with altered susceptibility to nucleoside analogs and uses thereof | EVIVAR MEDICAL PTY LTD. (AU) | 2005-07-14 | — | — | US | disclosed |
| CN-1639324-A | Viral variants with altered sensitivity to nucleoside analogs and uses thereof | MELBOURA HEALTH LTD (AU) | 2005-07-13 | — | — | CN | disclosed |
| WO-2005042733-A1 | HBV VARIANTS DETECTION AND APPLICATION | MELBOURNE HEALTH (AU) | 2005-05-12 | — | — | WO | disclosed |
| EP-1499712-A1 | HEPATITIS B VIRAL VARIANTS WITH REDUCED SUSCEPTIBILITY TO NUCLEOSIDE ANALOGS AND USES THEREOF | Melbourne Health (AU) | 2005-01-26 | — | — | EP | disclosed |
| EP-1476543-A1 | VIRAL VARIANTS WITH ALTERED SUSCEPTIBILITY TO NUCLEOSIDE ANALOGS AND USES THEREOF | Melbourne Health (AU) | 2004-11-17 | — | — | EP | disclosed |
| WO-2004009595-A1 | COMBINATION THERAPY WITH 1,3-DIOXOLANES AND INOSINE MONOPHOSPHATE DEHYDROGENASE INHIBITORS | TRIANGLE PHARMACEUTICALS, INC. (US) | 2004-01-29 | — | — | WO | disclosed |
| WO-2003087351-A1 | HEPATITIS B VIRAL VARIANTS WITH REDUSED SUSCEPTIBILITY TO NUCLEOSIDE ANALOGS AND USES THEREOF | MELBOURNE HEALTH (AU) | 2003-10-23 | — | — | WO | disclosed |
| WO-2003066841-A1 | VIRAL VARIANTS WITH ALTERED SUSCEPTIBILITY TO NUCLEOSIDE ANALOGS AND USES THEREOF | MELBOURNE HEALTH (AU) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060051743-A1 | Screening nucleic acid comprising sequence that encodes reverse transciptase domain of DNA polymerase for adefovir-resistant mutations; use in vaccine development | DNTT, HAVCR2, RNPEP | KDM4E 4334/4885ALDH1A1 4795/4885LMNA 1334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.